Quest Diagnostics (DGX) Stock
Leading US clinical laboratory company with extensive scale. Here's the price, business snapshot, and what's worth knowing about Quest Diagnostics in August 2026.
Quest Diagnostics (DGX) is a leading US clinical laboratory services company that provides diagnostic testing, information and services to healthcare providers, hospitals, employers and insurers. Its business is driven by volume of tests, reimbursement rates and specialised, higher-margin diagnostics such as molecular and genomics testing. The company benefits from scale, extensive logistics and long-term contracts but faces competition from other national labs, hospital systems and growing point-of-care testing. Key investor considerations include demand trends for routine and specialised tests, reimbursement and regulatory pressure, and capital investment in automation and new technologies. Quest has historically returned cash via dividends and buybacks, though investors should weigh yield against growth prospects and margin sensitivity. Market cap is about $20.54bn. This summary is for general educational purposes only and is not personalised investment advice; values can fall as well as rise and you should consider your circumstances or speak with a financial adviser.
Why It’s Moving
DGX steadies on higher estimates, but analysts still flag limited downside cushion
- Analysts have recently nudged estimates higher, which can ease some near-term pressure even as the stock still reflects modest downside risk.
- Quest Diagnostics has continued paying its quarterly dividend, keeping attention on cash generation and defensive income appeal.
- The broader healthcare and outpatient-services backdrop has stayed mixed, with investors weighing steady demand against slower growth expectations.
DGX steadies on higher estimates, but analysts still flag limited downside cushion
- Analysts have recently nudged estimates higher, which can ease some near-term pressure even as the stock still reflects modest downside risk.
- Quest Diagnostics has continued paying its quarterly dividend, keeping attention on cash generation and defensive income appeal.
- The broader healthcare and outpatient-services backdrop has stayed mixed, with investors weighing steady demand against slower growth expectations.
Sixth Month Growth Performance
When is the next earnings date for QUEST DIAGNOSTICS INC (DGX)?
Quest Diagnostics’ next earnings date is expected to be October 20, 2026. The report should cover Q3 2026 results. This timing is based on the company’s historical reporting pattern and current earnings-calendar estimates.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Quest Diagnostics' stock, anticipating significant growth potential from its current price.
Financial Health
Quest Diagnostics is performing well with strong revenue and cash flow, supporting its overall stability.
Dividend
Quest Diagnostics' low dividend yield of 0.87% may not appeal to dividend-focused investors. If you invested $1000, you would be paid $8.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Steady testing demand
Routine and chronic‑care testing provides consistent revenue streams, though volumes can shift with public‑health trends and reimbursement changes.
Diagnostic innovation
Growth in molecular and genomic testing and investments in automation may lift margins, but these require capital and carry technological risk.
Market dynamics
Industry consolidation and payer negotiations influence pricing power, so regulatory and competitive shifts can materially affect performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
